EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 3.0

Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study

Gaétan Deslee iD, Caroline Fabry-Vendrand iD, Elsa Salmi, Nolwenn Poccardi, Adrien Coriat, Idir Ghout, Caroline Eteve-Pitsaer, Nicola J Adderley iD, Henri Leleu

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s495086 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Gaétan Deslee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pneumologie, INSERM UMRS-1250, Centre Hospitalier Universitaire de Reims, Université Reims, Champagne-Ardenne, France. Hauptthemen laut MEDLINE: Adrenergic beta-2 Receptor Agonists, Bronchodilator Agents, Budesonide, Budesonide, Formoterol Fumarate Drug Combination. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-2 Receptor AgonistsBronchodilator AgentsBudesonideBudesonide, Formoterol Fumarate Drug CombinationFormoterol FumarateGlycopyrrolateMuscarinic AntagonistsPractice Patterns, Physicians'Pulmonary Disease, Chronic ObstructiveAgedFemaleHumansMaleMiddle AgedAdministration, InhalationCross-Sectional StudiesDatabases, FactualDrug CombinationsFranceGuideline AdherenceLungNebulizers and VaporizersPractice Guidelines as TopicPulmonologistsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

budesonide/glycopyrronium bromide/formoterol fumaratechronic obstructive pulmonary diseasemanagementtriple therapy

Substanzen

Adrenergic beta-2 Receptor AgonistsBronchodilator AgentsBudesonideBudesonide, Formoterol Fumarate Drug CombinationDrug CombinationsFormoterol FumarateGlycopyrrolateMuscarinic Antagonists

Autor:innen und Institutionen

  • Service de Pneumologie, INSERM UMRS-1250, Centre Hospitalier Universitaire de Reims, Université Reims, Champagne-Ardenne, France.
  • AstraZeneca, Courbevoie, France.
  • Cegedim Group, Boulogne-Billancourt, France.
  • Department of Applied Health Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
  • Public Health Expertise, Paris, Île-de-France, France.

ORCID-Profile: Gaétan Deslee, Caroline Fabry-Vendrand, Nicola J Adderley

Zitieren

APA

Deslee, G., Fabry-Vendrand, C., Salmi, E., Poccardi, N., Coriat, A., Ghout, I., Eteve-Pitsaer, C., Adderley, N. J., & Leleu, H. (2025). Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s495086

Vancouver

Deslee G, Fabry-Vendrand C, Salmi E, Poccardi N, Coriat A, Ghout I, et al. Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s495086

BibTeX
@article{Deslee2025,
  author = {Deslee, Gaétan and Fabry-Vendrand, Caroline and Salmi, Elsa and Poccardi, Nolwenn and Coriat, Adrien and Ghout, Idir and Eteve-Pitsaer, Caroline and Adderley, Nicola J and Leleu, Henri},
  title = {Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s495086}
}
Kostenlos starten →